Progressive efficacy improvements with quarterly intravenous ibandronate injections: The DIVA study long term extension

被引：0
|
作者：
Czerwinski, E.
Langdahl, B.
Stepan, J.
Grant, R.
Neate, C.
Bianchi, G.
机构：
[1] Krakow Med Ctr, Dept Med, Krakow, Poland
[2] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark
[3] Charles Univ Prague, Dept Internal Med, Prague, Czech Republic
[4] Hoffmann La Roche Inc, Nutley, NJ USA
[5] Roche Prod Ltd, Pharma Dev Med Biostat, Welwyn Garden City AL7 3AY, Herts, England
[6] Osped Coletta, Div Rheumatol, Genovese, Italy
来源：
CALCIFIED TISSUE INTERNATIONAL | 2007年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S121 / S121
页数：1
相关论文
共 50 条
  • [31] Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study
    Miller, P. D.
    Recker, R. R.
    Reginster, J. -Y.
    Riis, B. J.
    Czerwinski, E.
    Masanauskaite, D.
    Kenwright, A.
    Lorenc, R.
    Stakkestad, J. A.
    Lakatos, P.
    OSTEOPOROSIS INTERNATIONAL, 2012, 23 (06) : 1747 - 1756
  • [32] Low incidence of flu-like illness with intravenous ibandronate injections: DIVA 2-year results
    Bianchi, G.
    Sambrook, P. N.
    Lewiecki, E. M.
    Leigh, C.
    Mairon, N.
    Burdeska, A.
    Delmass, P. D.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 413 - 413
  • [33] Similar safety profile of intravenous ibandronate injection and daily oral ibandronate in postmenopausal osteoporosis: The DIVA study.
    Sambrook, P
    Bianchi, G
    Olszynski, WP
    Leigh, C
    Masanauskaite, D
    Bonvoisin, B
    Emkey, R
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S296 - S296
  • [34] Progressive bone density gains with once-monthly oral Ibandronate: The MOBILE study long-term extension.
    Lewiecki, E. Michael
    Reginster, Jean-Yves
    Elizondo-Alanis, Luis J.
    Neate, Colin
    Adami, Silvano
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S584 - S584
  • [35] Intermittent intravenous ibandronate injections are more effective than daily oral ibandronate for improving bone density at the hip: DIVA 2-year analysis
    Gonzalez Macias, J.
    Prince, R.
    Recker, R. R.
    Mairon, N.
    Masanauskaite, D.
    Hughes, C.
    Reid, D. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 418 - 418
  • [36] Intravenous ibandronate injections are at least as effective and similarly well tolerated as daily oral ibandronate in postmenopausal osteoporosis: 1-year results from DIVA
    Adami, S
    Nuti, R
    Czerwinski, E
    Hughes, C
    Ward, P
    Bonvoisin, B
    Tanko, LB
    BONE, 2005, 36 : S137 - S138
  • [37] The efficacy of monthly oral ibandronate (150mg) 15 maintained: Mobile study long-term extension
    Stepan, J.
    Riis, B. J.
    Sedarati, F.
    Neate, C.
    Felsenberg, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 533 - 533
  • [38] Novel ibandronate regimens in postmenopausal osteoporosis: Design of the dosing intravenous administration (DIVA) study
    Sambrook, P
    Reginster, JY
    Recker, RR
    Seeman, E
    Nuti, R
    Kelly, S
    Gilbride, J
    Bonvoisin, B
    OSTEOPOROSIS INTERNATIONAL, 2004, 15 : S118 - S118
  • [39] Renal tolerability profile of intermittent intravenous ibandronate injections in postmenopausal women with osteoporosis: DIVA 2-year analysis
    不详
    CALCIFIED TISSUE INTERNATIONAL, 2006, 78 : S125 - S125
  • [40] Intermittent intravenous ibandronate injections are an effective treatment option in postmenopausal osteoporosis: 2-year results from diva
    Eisman, J. A.
    Garcia-Hernandez, P. A.
    Ortiz-Luna, G.
    Ste-Marie, L. G.
    Hughes, C.
    Mairon, N.
    Masanauskaite, D.
    Delmas, P. D.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S212 - S212
12345